A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food
- Conditions
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT05337592
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT05327946
- Locations
- 🇺🇸
Florida Cancer Specialists-Sarasota-61670, Sarasota, Florida, United States
🇺🇸John Theurer Cancer Center, Hackensack, New Jersey, United States
🇨🇦Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1178
- Registration Number
- NCT05321082
- Locations
- 🇺🇸
Southeastern Research Center-Winston-Salem-61365, Winston-Salem, North Carolina, United States
🇺🇸Intermountain Medical Center-Murray-69497, Murray, Utah, United States
🇦🇷Centro de Investigaciones Metabolicas (CINME)-C.A.B.A-61553, C.a.b.a, Argentina
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1177
- Registration Number
- NCT05321069
- Locations
- 🇺🇸
Piedmont Healthcare-Atlanta-57055, Atlanta, Georgia, United States
🇺🇸Weill Cornell Medicine-New York-59955, New York, New York, United States
🇺🇸Southeastern Research Center-Winston-Salem-61365, Winston-Salem, North Carolina, United States
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 82
- Registration Number
- NCT05296733
- Locations
- 🇸🇰
SUMMIT CLINICAL RESEARCH, s.r.o., Bratislava, Slovakia
🇺🇸Arizona Liver Health, Chandler, Arizona, United States
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT05285982
- Locations
- 🇺🇸
Weill Cornell Medicine-New York-60569, New York, New York, United States
🇦🇷Hospital de Pediatria Prof. Dr. Juan P. Garrahan, Caba, Argentina
🇪🇸Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 90
- Registration Number
- NCT05282121
- Locations
- 🇺🇸
Floridian Clinical Research-Miami Lakes-68368, Miami Lakes, Florida, United States
🇳🇱Amsterdam UMC, location VUMC, Amsterdam, Netherlands
🇪🇸Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 62
- Registration Number
- NCT05278104
- Locations
- 🇩🇪
Universitätsklinikum Aachen, AöR, Aachen, Germany
🇩🇪Rheinhessen-Fachklinik Alzey, Alzey, Germany
🇩🇪Universitätsklinikum Bonn AöR, Bonn, Germany
A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of Nintedanib
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21
- Registration Number
- NCT05262751
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1200
- Registration Number
- NCT05262764
- Locations
- 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan